Duke Management Company and Osage University Partners have invested in the genome editing technology spinout from Duke University.

Precision BioSciences, a US-based genomic medicine developer spun out from Duke University, completed a $110m series B round yesterday that included the institution’s endowment arm Duke Management Company. Spinout-focused investment firm Osage University Partners also contributed to the round, as did pharmaceutical firms Amgen and EMS, and real estate investment trust Alexandria Real Estate Equities.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.